The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin.
Ontology highlight
ABSTRACT: The aim was to compare ovarian response and clinical outcome of potential high-responders after stimulation with highly purified menotropin (HP-hMG) or recombinant follicle-stimulating hormone (rFSH) for in vitro fertilisation/intracytoplasmic sperm injection. Retrospective analysis was performed on data collected in two randomized controlled trials, one conducted following a long GnRH agonist protocol and the other with an antagonist protocol. Potential high-responders (n?=?155 and n?=?188 in the agonist and antagonist protocol, respectively) were defined as having an initial anti-Müllerian hormone (AMH) value >75th percentile (5.2?ng/ml). In both protocols, HP-hMG stimulation in women in the high AMH category was associated with a significantly lower occurrence of high response (?15 oocytes retrieved) than rFSH stimulation; 33% versus 51% (p?=?0.025) and 31% versus 49% (p?=?0.015) in the long agonist and antagonist protocol, respectively. In the potential high-responder women, trends for improved live birth rate were observed with HP-hMG compared with rFSH (long agonist protocol: 33% versus 20%, p?=?0.074; antagonist protocol: 34% versus 23%, p?=?0.075; overall population: 34% versus 22%, p?=?0.012). In conclusion, the type of gonadotropin used for ovarian stimulation influences high-response rates and potentially clinical outcome in women identified as potential high-responders.
SUBMITTER: Arce JC
PROVIDER: S-EPMC4059219 | biostudies-literature | 2014 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA